Drug Profile
Avasopasem manganese - Galera Therapeutics
Alternative Names: Avasopasem; GC 4419Latest Information Update: 17 Nov 2023
Price :
$50
*
At a glance
- Originator Galera Therapeutics
- Class Anti-inflammatories; Antifibrotics; Antineoplastics; Aza compounds; Chemoprotectants; Cyclohexanes; Pyridines; Small molecules
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Stomatitis
- Phase II COVID 2019 infections; Mucositis; Oesophagitis
- Phase I/II Head and neck cancer; Pancreatic cancer
- No development reported Renal failure; Unspecified
- Discontinued Fibrosis
Most Recent Events
- 02 Nov 2023 Updated efficacy and safety data from the phase III ROMAN trial in Stomatitis presented at the American Society of Nephrology Kidney Week meeting (ASN-2023)
- 31 Oct 2023 Galera Therapeutics receives minutes of the Type A meeting from the US FDA for avasopasem manganese in Stomatitis
- 20 Oct 2023 Meta-analysis adverse events and efficacy data from the phase-III ROMAN and phase-IIb GT-201 trials presented at the European Society for Medical Oncology Congress (ESMO-2023)